Unknown

Dataset Information

0

Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis.


ABSTRACT:

Background

The prognostic significance of p53 aberration in hepatocellular carcinoma (HCC) remains inconclusive. This systematic review and meta-analysis aimed to provide comprehensive evidence on the association of p53 alterations with recurrence-free survival (RFS) and overall survival (OS) in HCC patients.

Methods

Systematic literature searches were conducted until July 2010. Meta-analysis was performed to estimate prognostic effects of p53 alterations on patient outcomes in HCC. Sensitivity and subgroup analyses were also conducted in the meta-analysis.

Results

Thirty-seven studies (7 tumour p53 mutation, 23 tumour p53 expression and 7 serum anti-p53 antibodies) were included in the systematic review and meta-analysis. The average percentages of p53 mutation, p53 expression upregulation and anti-p53 antibody level elevation in HCC patients were 31.5%, 35.0% and 23.8%, respectively. Tumour p53 alterations were associated significantly with poor patient outcomes in HCC: the summary hazard ratio (HR) of mutant p53 versus wild type p53 phenotype was 2.58 [95% confidence interval (CI): 1.96-3.41] for OS and 3.19 [95% CI: 2.21-4.60] for RFS, respectively; and the summary HR of upregulated p53 expression versus low/undetectable p53 expression was 1.68 [95% CI: 1.49-1.90] for OS and 1.89 [95% CI: 1.34-2.66] for RFS, respectively. However, elevated serum anti-p53 antibody was only associated with poor OS in HCC group with a high proportion of (? 50%) of hepatitis C virus (HCV) infection [HR: 1.92; 95% CI: 1.30-2.85]. Moreover, sensitivity analyses showed that the results of meta-analyses were not altered.

Conclusion

HCC patients with p53 mutation and upregulated expression in tumour tissue have a shorter OS and RFS than patients with wild type p53 and low/undetectable p53 expression. However, the prognostic value of serum anti-p53 antibody is required to be further examined.

SUBMITTER: Liu J 

PROVIDER: S-EPMC3395767 | BioStudies | 2012-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6687027 | BioStudies
2017-01-01 | S-EPMC5458210 | BioStudies
2021-01-01 | S-EPMC7807881 | BioStudies
2015-01-01 | S-EPMC4351250 | BioStudies
1000-01-01 | S-EPMC6352338 | BioStudies
2012-01-01 | S-EPMC3394972 | BioStudies
2016-01-01 | S-EPMC4838250 | BioStudies
2020-01-01 | S-EPMC7751218 | BioStudies
2014-01-01 | S-EPMC3907387 | BioStudies
2017-01-01 | S-EPMC5410268 | BioStudies